Performance &

Progress

Paradigm Biopharmaceuticals Limited (ASX:PAR) is an ASX-listed biotechnology company focused on repurposing Pentosan Polysulfate Sodium (PPS), an FDA-approved drug that has a long track record of safely treating inflammation over 60 years. The Company’s primary focus is on repurposing PPS (under the name ZILOSUL®) to treat Osteoarthritis (OA), with an addressable population of over 72m in key markets (US, EU5, AU, CAN).

Want more details about our development pipeline?

Current shareholders: want to access and update your personal details?

ASX:PAR
_ _0.00

0.00

0.00%

Prev. close

Volume

 $0.00

0

Open

High

Low

 $0.00

$0.00

$0.00

Powered by Share Link

Last updated – 

Next Investor Event
EventParadigm AGM
LocationMelbourne, Victoria
DateTBA

Last updated 08/06/22 1:10pm

ASX Performance

ASX Performance

Market Reports

Presentations

paradigm icons white _Video
Investor Webinar
Video content
July 21, 2022
paradigm icons white _Article
Investor Update
Paradigm Presentation
July 21, 2022
paradigm icons white _Video
Annual General Meeting 2022
Video Content
January 25, 2022
paradigm icons white _Video
JP Morgan Healthcare Conference 2022
Event video
January 13, 2022
paradigm icons white _Article
JP Morgan Healthcare Conference 2022
Paradigm presentation
January 12, 2022
paradigm icons white _Video
Investor Webinar
Video content
December 3, 2021
paradigm icons white _Article
Investor Webinar
Paradigm presentation
December 2, 2021
paradigm icons white _Video
2021 Investor Call
Video Content
August 5, 2021
paradigm icons white _Article
Bell Potter healthcare update
Paradigm presentation
August 3, 2021
paradigm icons white _Video
JP Morgan Healthcare Conference 2021
Video content
January 13, 2021
paradigm icons white _Video
Inaugural R&D Day
Paradigm presentation
December 21, 2020
paradigm icons white _Article
Inaugural R&D Day – LUMI guide
Online meeting guide
December 1, 2020
paradigm icons white _Video
Paradigm Virtual AGM 2020
Video content
November 24, 2020
paradigm icons white _Article
Bell Potter Emerging Leaders Conference
Paradigm presentation
September 1, 2020
paradigm icons white _Article
OA/BME Expanded Access Program Results
Paradigm Presentation
July 30, 2020
paradigm icons white _Video
OA/BME Expanded Access Program Film
Video content
July 23, 2020
paradigm icons white _Audio
Investor Call 2020
Virtual investor call
April 8, 2020
paradigm icons white _Video
NWR Small Cap Virtual Conference
Video content
March 31, 2020
paradigm icons white _Article
NWR Small Cap Virtual Conference
Paradigm presentation
March 27, 2020
paradigm icons white _Article
MPS VI poster, World Symposium 2020
Paradigm poster
January 20, 2020
paradigm icons white _Article
Paradigm AGM, 2019
Paradigm presentation
November 7, 2019
paradigm icons white _Article
Phase 2b OA/BME Clinical Trial Results
Paradigm Presentation
December 18, 2018
paradigm icons white _Article
RWE of clinical outcomes in OA patients with BME administered PPS
Prof J Krishnan ISKSAA Presentation
June 21, 2018

Product Developments

To view our approach to product development, click here

Development Pipeline

OA MPS VI MPS I HF ARDS RRV CHIKV AR

P.O.C  – Proof of Concept | REG. – Registration

POC – Proof of Concept | P1 – Phase One | P2 – Phase Two
P3 – Phase Three | REG – Registration

Clinical Trials

Paradigm Biopharmaceuticals Ltd is currently recruiting for clinical trials.

Please note that Paradigm Biopharmaceuticals Ltd is unable to discuss individuals’ eligibility for clinical trials or any matters relating to your condition.

Contact information for centres conducting clinical trials can be found in the links below.